Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension

Frontiers in Cardiovascular Medicine

Feifei Lv¹  Lanjuan Li²  Qiaoling Pan²  Jinfeng Yang²  Hongcui Cao²  Xinyu Sheng²  Xiaowei Shi²  Jiong Yu²  Jing Ma³  Jian Wu⁴ 

[1] Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China;State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China;Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;Department of Laboratory Medicine, The First People's Hospital of Yancheng City, Yancheng, China;

关键词: angiotensin-converting enzyme inhibitors;    angiotensin receptor blockers;    COVID-19;    hypertension;    SARS-CoV-2;   

DOI  :  10.3389/fcvm.2021.577398

来源: Frontiers

【 授权许可】

CC BY